Is Clindamycin + Tretinoin registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 1 valid registration of Clindamycin + Tretinoin, including ACRETIN C 1.2% + 0.025 % GEL (1.2,0.025 %,%, Gel, SAR 33.80).

Is Clindamycin + Tretinoin approved by the US FDA?

Drugs@FDA lists 5 application product lines for Clindamycin + Tretinoin, including ZIANA (Prescription); VELTIN (Prescription); CLINDAMYCIN PHOSPHATE AND TRETINOIN (Prescription); CLINDAMYCIN PHOSPHATE AND TRETINOIN (Prescription); CLINDAMYCIN PHOSPHATE AND TRETINOIN (Prescription).

Active substances

Clindamycin + Tretinoin

SFDA 1
US FDA 5
Health Canada 1
NHS prices 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
ACRETIN C 1.2% + 0.025 % GEL	1.2,0.025 %,%	Gel · Topical	1 Tube	SAR 33.80	Generic · Prescription	Jamjoom Pharmaceuticals Factory Company	Valid

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
ZIANA	1.2%;0.025%	gel · topical	BAUSCH	Prescription	7 Nov 2006
VELTIN	1.2%;0.025%	gel · topical	CHARTWELL RX	Prescription	16 Jul 2010
CLINDAMYCIN PHOSPHATE AND TRETINOIN	1.2%;0.025%	gel · topical	ACTAVIS MID ATLANTIC	Prescription	12 Jun 2015
CLINDAMYCIN PHOSPHATE AND TRETINOIN	1.2%;0.025%	gel · topical	SOLARIS PHARMA CORP	Prescription	10 Feb 2022
CLINDAMYCIN PHOSPHATE AND TRETINOIN	1.2%;0.025%	gel · topical	ENCUBE	Prescription	1 Sep 2023

Canada Canada — marketed products (Health Canada)

Brand	DIN	Strength	Form · route	Company
BIACNA TOPICAL GEL	02359685	1.2 % / W/W; 0.025 % / W/W	GEL · TOPICAL	BAUSCH HEALTH, CANADA INC.

Prices — United States and England

Source	Product as listed	Price	Unit / pack	Date
NHS Drug Tariff	Clindamycin 1% / Tretinoin 0.025% gel	£11.94	30 gram	1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.